CT26.CL25 Cells - Intestine cancer cell lines
Produktgrößen
1 each
£755,00
305353-1EACH
Über dieses Produkt
- SKU:
- 305353
- Zusätzliche Namen:
- CT26-clone 25
- CE/IVD:
- Our cells are provided for in vitro laboratory research purposes exclusively and are not intended fo
- Weitere Details:
- The CT26.CL25 cell line is a murine colon carcinoma model derived from the parental CT26 cell line, which is a chemically induced, undifferentiated colon carcinoma originating from BALB/c mice. CT26.CL25 has been genetically modified to express the B Beta-galactosidase (B Beta-gal) protein, making it an excellent model for studying tumor immunology and immunotherapy, particularly in the context of tumor-associated antigens (TAAs). This modification allows for specific immunological studies targeting B Beta-gal as a neoantigen, facilitating research into the mechanisms of tumor immune evasion and the development of cancer vaccines or adoptive cell therapies. CT26.CL25 has been employed in preclinical models to investigate immune responses and the efficacy of immunotherapies, such as the use of dendritic cells (DCs) loaded with tumor-associated antigens. Studies have shown that immunization strategies using DCs pulsed with peptides derived from retroviral antigens, like gp70, can elicit robust anti-tumor immune responses. In experimental models, the activation of CD8+ cytotoxic T lymphocytes (CTLs) specific for gp70 was observed, demonstrating the cell line's utility in testing immunotherapeutic approaches. However, the immunization with such peptide-loaded DCs has shown limitations, particularly in treating established metastases, highlighting the challenges in translating prophylactic immune responses into therapeutic efficacy. Additionally, CT26.CL25 is often used in research to test the efficacy of combined immunotherapy approaches, such as the use of immune checkpoint inhibitors or cancer vaccines. For instance, studies have evaluated the impact of metronomic chemotherapy combined with immune checkpoint inhibitors, where the induction of immunogenic cell death (ICD) in CT26.CL25 has been crucial for enhancing the anti-tumor immune response. These investigations have demonstrated that targeting immune checkpoints can synergize with chemotherapy to increase tumor rejection rates and establish long-term immunological memory.
- Versandbedingungen:
- Dry Ice
- Lagerbedingungen:
- Liquid N2, -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- Cytion
- Typ:
- Cells: Cell Lines
- Datenblatt des Herstellers:019301054dc37914b318f5b7e2dbad9b